Bullous pemphigoid
Conditions
Interventions
Stapokibart Group:Stapokibart combined with oral glucocorticoids
Mycophenolate Mofetil Group:Mycophenolate Mofetil combined with oral glucocorticoids
Sponsors
Wuhan Hospital of Integrated Traditional Chinese and Western Medicine (Wuhan First Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old, gender not restricted; 2. Patients who have been diagnosed with bullous pemphigoid; 3. Disease activity score (BPDAI) reaches moderate to severe level (>= 20); 4. Able to follow up as required by the study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Active severe infection or other conditions deemed unsuitable by investigators. 2.Known hypersensitivity/contraindications to study-related medications. 3.Pregnancy or breastfeeding. 4.Recent participation in other interventional clinical studies or poor compliance. 5.Any other condition judged by investigators to make the participant ineligible.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients achieving clinical remission at Week 36; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pruritus score;Cumulative glucocorticoid dose (prednisone equivalent);Incidence of adverse events;Time to disease control;Change from baseline in BPDAI score;Anti-epidermal basement membrane zone antigen 230;Anti-epidermal basement membrane zone antigen 180; | — |
Countries
China
Contacts
Public ContactJinbo Chen
Wuhan Hospital of Integrated Traditional Chinese and Western Medicine (Wuhan First Hospital)
Outcome results
None listed